A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer will be gaining exclusive rights to 3SBio’s investigational PD-1 and VEGF-targeted bispecific antibody in a deal worth over $6bn. The candidate, SSGJ-707, is currently being evaluated in ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Investing.com-- Shares of 3SBio Inc (HK: 1530) skyrocketed in Hong Kong trade on Tuesday after the company licensed an experimental cancer treatment to U.S. drugmaker Pfizer Inc (NYSE: PFE), with the ...

Citi lifts 3SBio stock rating, doubles price target to HK$13.00 Open in App Get 45% Off Sign In Free Sign Up ...